Company history

1991
1992
1994
1995
1998
2002
2004
2005
2008
2010
2011
2012
2013
2014
2015
2016
2017
2019
2020
1991

Company foundation. Larisa Prokopyeva, senior researcher at the Altai Federal Research and Production Center, registers Evalar company with only 12 employees.

1992

Received the first patent for an industrial technology for processing Altai Mumijo.

1994

The production of MCC Ankir-B tablets begins, providing the young enterprise with a huge increase in sales and access to the pharmaceutical market in Russia.

1995

The development of its own pharmacy chain in the Altai Territory. The first pharmacies opened in Biysk.

1998

—ultivation of Evalarís own plantations in Altai

2002

Entering CIS and Baltic markets. The company's portfolio consists of over 90 brands.

2004

Launch of Evalarís new manufacturing facility. Production of tableted and galenic forms. Licensed manufacturing facility for producing extracts from medicinal raw materials (5 tons of dry extracts per month).

2005

Opening of the Moscow representative office.

2008

The production unit for galenicals is put into operation. The companyís staff includes 1000 people.

2010

The launch of Evalar Moscow pharmacy chain.

2011

Decision to expand the portfolio and build a new manufacturing facility.

2012

The Company obtains the certificate on conformity of the manufacturing facilities to the international standard of quality ISO 9001: 2008.

2013

New manufacturing facility design completion and state examination approval.

2014
Evalar gets the certificate for compliance with the GMP quality standard, issued by the International division of the National Sanitary Foundation of the United States (NSF International).
2015

Evalar obtains the certificate of conformity with the GMP from the Ministry of Health of Australia and enters the countryís local market. Representative offices open in Paris and Sydney. The total number of companyís employees exceeds 1300 people. The portfolio of the Altai manufacturer includes more than 300 SKU. Evalar expands its production twofold and builds another plant. The investments in the project exceed $100 million. The company continues to hold the leading position in the Russian market of natural medicinal products. The pharmacy chain Evalar has about 60 pharmacies in large cities of Russia. The annual turnover of the joint-stock company is close to 10 billion rubles.

2016

Evalar celebrates its 25th anniversary. Evalar is included in the TOP-5 of the largest domestic pharmaceutical manufacturers. The company is building a second manufacturing plant in the Altai Territory, with a productive capacity of 6 billion tablets and capsules per year.

2017

The company receives a GMP certificate following the results of a national audit carried out by the Ministry of Industry and Trade of the Russian Federation for compliance with the Rules of Good Manufacturing Practice (Order No. 916 of the Ministry of Industry and Trade of 14.06.13).

2019
Launch of the first line intended for the production of herbal medicines.
2020
Launch of the second line in a new manufacturing  facility in the Altai Territory, intended for the production of synthetic medicine.